SecurityBridge Announces CEO Transition to Accelerate Global Expansion
12.1.2026 15:15:00 CET | Business Wire | Press release
SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the appointment of Jesper Zerlang as Chief Executive Officer, effective January 1, 2026. Zerlang transitions from his role as Chairman of the Board, a position he has held for the past 12 months, as the company enters its next phase of international expansion, backed by funds advised by BUBregal Unternehmerkapital (BU).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112824449/en/

Jesper Zerlang appointed Chief Executive Officer, SecurityBridge
SecurityBridge protects SAP environments for large enterprises by reducing cyber risk across mission-critical SAP landscapes. The company is trusted by global customers to safeguard systems that power core operations, financial processes, supply chains, and digital transformation programs.
“SecurityBridge is uniquely positioned at the intersection of cybersecurity and SAP – a domain I know deeply and care about profoundly,” said Jesper Zerlang,CEO of SecurityBridge. “Over the past year, as Chairman, I have seen firsthand the strength of the team, the technology, and the outcomes we deliver for customers. With BU’s support and a clear ambition to scale internationally, I am excited to step into the CEO role to accelerate global impact while raising the bar on trust and customer outcomes.”
Leadership Transition and Founder Roles
SecurityBridge founders Christoph Nagy and Ivan Mans will transition out of their day-to-day operational roles as CEO andCTO, respectively. They will remain strategically central to the business in pivotal roles focused on product evangelismandhigh-impact, customer-driveninitiatives,leveraging their SAP engineering depth, credibility, and long-term product vision.
“SecurityBridge has grown into a remarkable company with a strong foundation and a clear mission,” said Nagy, Co-Founder of SecurityBridge. “This transition strengthens the company’s ability to scale globally while allowing us to focus where we create the greatest value for customers: product leadership, innovation, and engagement with the SAP ecosystem.”
“We are fully supportive of this exciting transition and look forward to contributing in roles that amplify our technical focus and customer impact. SecurityBridge’s opportunity ahead is significant, and this step positions the company strongly for the next stage,” added Ivan Mans, Co-Founder of SecurityBridge.
About SecurityBridge (SB)
SecurityBridge is the leading provider of a comprehensive, SAP-native cybersecurity platform, trusted by organizations worldwide to safeguard their most critical business systems. Our platform seamlessly integrates real-time threat monitoring, vulnerability management, and compliance capabilities directly into the SAP environment, empowering organizations to protect their data’s integrity, confidentiality, and availability with minimal manual effort. With a proven track record, including a stellar customer success rating and over 8,000 SAP systems secured globally, SecurityBridge stands out for its ability to accurately provide a 360° view of the SAP security posture, ease of use, rapid implementation, and transparent licensing. We are committed to innovation, transparency, and customer-centricity, ensuring businesses can confidently navigate the evolving landscape of SAP security threats.
For more information, visit www.securitybridge.com
About BU Bregal Unternehmerkapital
BU Bregal Unternehmerkapital (“BU”) is a leading investment firm with offices in Zug, Munich, Milan, and London. With more than €7bn Assets under Management (AUM), BU is the largest mid-cap investor headquartered in the DACH region. The funds advised by BU invest in mid-sized companies based in Germany, Switzerland, Italy, and Austria. With the mission to be the partner of choice for entrepreneurs and family-owned businesses, BU seeks to partner with market leaders and “hidden champions” with strong management teams and breakout potential. Since its founding in 2015, the funds advised by BU have invested in more than 150 companies with almost 32,000 employees. Thereby, more than 11,000 jobs have been created. BU supports entrepreneurs and families as a strategic partner to develop, internationalize, and digitize their businesses, while helping them generate sustainable value on a responsible basis with the next generation in mind.
For more information, please visit www.bu-partners.ch/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260112824449/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom